• Je něco špatně v tomto záznamu ?

Population Pharmacokinetics of Prophylactic Cefazolin in Cardiac Surgery with Standard and Minimally Invasive Extracorporeal Circulation

P. Šantavý, M. Šíma, O. Zuščich, V. Kubíčková, D. Michaličková, O. Slanař, K. Urbánek

. 2022 ; 11 (11) : . [pub] 20221109

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031329

The objectives of this study were to develop a population pharmacokinetic model of prophylactically administered cefazolin in patients undergoing cardiac surgery with and without the use of the cardiopulmonary bypass of both existing types-standard (ECC) and minimallyu invasive extracorporeal circulation (MiECC)-and to propose cefazoline dosing optimization based on this model. A total of 65 adult patients undergoing cardiac surgery were recruited to this clinical trial. A prophylactic cefazolin dose of 2 g was intravenously administered before surgery. Blood samples were collected using a rich sampling design and cefazolin serum concentrations were measured using the HPLC/UV method. The pharmacokinetic population model was calculated using a nonlinear mixed-effects modeling approach, and the Monte Carlo simulation was used to evaluate the PK/PD target attainment. The population cefazolin central volume of distribution (Vd) of 4.91 L increased by 0.51 L with each 1 m2 of BSA, peripheral Vd of 22.07 L was reduced by 0.77 L or 0.79 L when using ECC or MiECC support, respectively, while clearance started at 0.045 L/h and increased by 0.49 L/h with each 1 mL/min/1.73 m2 of eGFR. ECC/MiECC was shown to be covariate of cefazolin Vd, but without relevance to clinical practice, while eGFR was most influential for the PK/PD target attainment. The standard dose of 2 g was sufficient for PK/PD target attainment throughout surgery in patients with normal renal status or with renal impairment. In patients with augmented renal clearance, an additive cefazolin dose should be administered 215, 245, 288 and 318 min after the first dose at MIC of 4, 3, 2 and 1.5 mg/L, respectively.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031329
003      
CZ-PrNML
005      
20230127131131.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/antibiotics11111582 $2 doi
035    __
$a (PubMed)36358235
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Šantavý, Petr $u Department of Cardiac Surgery, Faculty of Medicine and Dentistry, Palacký University, University Hospital, Olomouc 779 00, Czech Republic
245    10
$a Population Pharmacokinetics of Prophylactic Cefazolin in Cardiac Surgery with Standard and Minimally Invasive Extracorporeal Circulation / $c P. Šantavý, M. Šíma, O. Zuščich, V. Kubíčková, D. Michaličková, O. Slanař, K. Urbánek
520    9_
$a The objectives of this study were to develop a population pharmacokinetic model of prophylactically administered cefazolin in patients undergoing cardiac surgery with and without the use of the cardiopulmonary bypass of both existing types-standard (ECC) and minimallyu invasive extracorporeal circulation (MiECC)-and to propose cefazoline dosing optimization based on this model. A total of 65 adult patients undergoing cardiac surgery were recruited to this clinical trial. A prophylactic cefazolin dose of 2 g was intravenously administered before surgery. Blood samples were collected using a rich sampling design and cefazolin serum concentrations were measured using the HPLC/UV method. The pharmacokinetic population model was calculated using a nonlinear mixed-effects modeling approach, and the Monte Carlo simulation was used to evaluate the PK/PD target attainment. The population cefazolin central volume of distribution (Vd) of 4.91 L increased by 0.51 L with each 1 m2 of BSA, peripheral Vd of 22.07 L was reduced by 0.77 L or 0.79 L when using ECC or MiECC support, respectively, while clearance started at 0.045 L/h and increased by 0.49 L/h with each 1 mL/min/1.73 m2 of eGFR. ECC/MiECC was shown to be covariate of cefazolin Vd, but without relevance to clinical practice, while eGFR was most influential for the PK/PD target attainment. The standard dose of 2 g was sufficient for PK/PD target attainment throughout surgery in patients with normal renal status or with renal impairment. In patients with augmented renal clearance, an additive cefazolin dose should be administered 215, 245, 288 and 318 min after the first dose at MIC of 4, 3, 2 and 1.5 mg/L, respectively.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University, General University Hospital, Prague 128 00, Czech Republic $1 https://orcid.org/000000026541738X
700    1_
$a Zuščich, Ondřej $u Department of Cardiac Surgery, Faculty of Medicine and Dentistry, Palacký University, University Hospital, Olomouc 779 00, Czech Republic
700    1_
$a Kubíčková, Vendula $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacký University, University Hospital, Hněvotínská 3, 775 15 Olomouc, Czech Republic
700    1_
$a Michaličková, Danica $u Department of Pharmacology, First Faculty of Medicine, Charles University, General University Hospital, Prague 128 00, Czech Republic $1 https://orcid.org/0000000296909846
700    1_
$a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University, General University Hospital, Prague 128 00, Czech Republic
700    1_
$a Urbánek, Karel $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacký University, University Hospital, Hněvotínská 3, 775 15 Olomouc, Czech Republic $1 https://orcid.org/0000000234611649
773    0_
$w MED00195446 $t Antibiotics (Basel, Switzerland) $x 2079-6382 $g Roč. 11, č. 11 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36358235 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131122 $b ABA008
999    __
$a ok $b bmc $g 1889460 $s 1182662
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 11 $c 11 $e 20221109 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics $x MED00195446
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Možnosti archivace